Takeda chief talks up M&A; Inotek lines up a $65M IPO;

@FierceBiotech: China's Innovent banks $100M to cash in on the biosimilar boom. Report | Follow @FierceBiotech

@JohnCFierce: So Martin Pule, who got his start with Brenner at Baylor on CAR-T ($CELG, $BLUE) went on the Cellectis deal ($ALCLS) is now CSO at Autolous. | Follow @JohnCFierce

@DamianFierce: @IAmBiotech weighs in on Obama's precision medicine plan. More | Follow @DamianFierce

> Incoming Takeda CEO Christophe Weber again touted his yen for dealmaking, saying the Japanese drugmaker will wade into the M&A market as soon as it completes its ongoing reorganization. News

> Inotek Pharmaceuticals has set terms for a $65 million IPO, raising money to support its work on an eye drop for glaucoma. More

> Industry group BIO applauded President Barack Obama's move to encourage research in personalized medicine, with CEO Jim Greenwood adding that a "large-scale national research commitment to chronic conditions would identify precursors and early signs of disease or disease risk to unlock the root causes of these conditions that threaten the health of our loved ones and undermine our nation's fiscal health." Release

Medical Device News

@FierceMedDev: SV Bio changes name to Lifecode, plans rollout of NGS cancer assay. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Celator's delivery platform results in FDA's fast-track designation for its cancer candidate. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: J&J settles the score with over 100 vaginal mesh plaintiffs. More | Follow @EmilyWFierce

> Welch Allyn buys eye exam provider, demonstrating device industry's growing interest in services. More

> China announces landmark medical device GSP rules. Report

Pharma News

@FiercePharma: Report: Livestock research lab prioritizes profits over animal health. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: UK's MHRA expands its ban of Wockhardt's plant in Chikalthana, India to include all APIs. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Incoming Takeda chief ready to jump on the M&A train with reorg in place. Report | Follow @CarlyHFierce

> Rooting for a French CEO at Sanofi? Take another name off your list of prospects. Story

> Novartis eyes psoriasis dominance with new approvals for Cosentyx. Article

Vaccines News

> After rocky flu season, vaccinemakers may want to follow Novartis' lead. Story

> Disneyland measles outbreak adds fuel to heated anti-vaccination debate. Item

> J&J forms consortia to accelerate Ebola vaccine development, gets €100M boost from IMI. News

> Study: GSK's malaria vaccine may not be effective when used with bed nets. More

> MSF urges GSK, Pfizer to slash pneumococcal vaccine prices. Report

Pharma Manufacturing News

> Manufacturing key to getting more effective flu jabs to market faster. Story

> Gulf Pharmaceutical commits to sterile injectable plant in Ethiopia. Report

> FDA finds more counterfeit Cialis, warns consumers. Article

> U.K. expands Wockhardt ban. More

> Biologics manufacturing helps Lonza to early turnaround. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.